Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples

被引:23
作者
Boobis, AR
McKillop, D
Robinson, DT
Adams, DA
McCormick, DJ
机构
[1] Zeneca Pharmaceut, Dept Safety Med, Drug Kinet Grp, Macclesfield SK10 4TG, Cheshire, England
[2] Imperial Coll Sci Technol & Med, Sch Med, Div Med, Clin Pharmacol Sect, London W12 0NN, England
[3] Sanofi Winthrop Ltd, Sanofi Res Div, Alnwick NE66 2JH, England
[4] BASF Pharma, Knoll Pharmaceut, Nottingham NG2 3AA, England
关键词
D O I
10.1080/004982598239416
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Although the importance of in vitro technology in supporting drug development is widely accepted, there is no real consensus about which approaches should be taken, which substrates should be used, or on the reliability and application of in vitro data. Consequently, as part of a collaborative project to characterize human liver with respect to the major forms of cytochrome P450, an interlaboratory comparison of the analysis of samples for form-specific activities was undertaken. 2. Microsomal fractions were isolated from five different human liver samples taken from the liver bank maintained at the Royal Postgraduate Medical School (RPMS). Aliquots from the five samples were sent to the 11 collaborating laboratories for characterization using their in-house, form-specific assays for cytochrome P450 activities. Although each laboratory assayed protein concentration, total cytochrome P450 content and enzyme activities were calculated using the protein estimation generated by RPMS to eliminate this possible source of variability. 3. With the exception of one laboratory, all estimates of protein concentration were similar (coefficient of variation, CoV, 9-13 %) and the rank-order of the five samples was consistent across the laboratories. There was greater variability in the estimates of total cytochrome P450 content (CoV 28-43 %), although again rank order of the samples across laboratories was fairly consistent. 4. The various laboratories used a number of different probe substrates, together with a range of conditions (substrate concentration, time of incubation, amount of protein), to assay for activity of CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4. However, apart from the occasional outlier, the five samples were ranked for activity of all these forms of cytochrome P450 with a high degree of consistency by the various laboratories and the choice of substrate had no appreciable effect on the ranking of the samples. 5. While this interlaboratory comparison has shown that greater consistency in the approach to in vivo determination of drug-metabolizing activity is desirable, there was little indication that any particular approach or substrate was superior to the others.
引用
收藏
页码:493 / 506
页数:14
相关论文
共 49 条
[1]  
Balls M, 1997, ATLA-ALTERN LAB ANIM, V25, P33
[2]   COMPARISON OF CAFFEINE METABOLISM BY SLICES, MICROSOMES AND HEPATOCYTE CULTURES FROM ADULT HUMAN-LIVER [J].
BERTHOU, F ;
RATANASAVANH, D ;
RICHE, C ;
PICART, D ;
VOIRIN, T ;
GUILLOUZO, A .
XENOBIOTICA, 1989, 19 (04) :401-417
[3]   MONO-OXYGENASE ACTIVITY OF HUMAN-LIVER IN MICROSOMAL FRACTIONS OF NEEDLE-BIOPSY SPECIMENS [J].
BOOBIS, AR ;
BRODIE, MJ ;
KAHN, GC ;
FLETCHER, DR ;
SAUNDERS, JH ;
DAVIES, DS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (01) :11-19
[4]  
BROLY F, 1990, DRUG METAB DISPOS, V18, P362
[5]   ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE [J].
BROSEN, K ;
ZEUGIN, T ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :609-617
[6]  
COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
[7]  
*COMM PROP MED PRO, 1997, IN PRESS NOT GUID IN
[8]  
Ebner T, 1995, MOL PHARMACOL, V48, P1078
[9]   CATALYTIC ACTIVITIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE CYTOCHROME-P450 (CYP2D6) EXPRESSED IN YEAST [J].
ELLIS, SW ;
CHING, MS ;
WATSON, PF ;
HENDERSON, CJ ;
SIMULA, AP ;
LENNARD, MS ;
TUCKER, GT ;
WOODS, HF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (04) :617-620
[10]   SACCHAROMYCES-CEREVISIAE - AN ALTERNATIVE SOURCE FOR HUMAN MICROSOMAL LIVER-ENZYMES AND ITS USE IN DRUG-INTERACTION STUDIES [J].
EUGSTER, HP ;
SENGSTAG, C .
TOXICOLOGY, 1993, 82 (1-3) :61-73